Compugen (Israeli company)

Compugen Ltd.
Public
Traded as NASDAQ: CGEN
TASE: CGEN
Industry Biotechnology
Founded 1993 (1993)
Founder Eli Mintz
Simchon Faigler
Amir Natan
Headquarters Holon, Israel
Key people
 Martin Gerstel (Chairman)
Anat Cohen-Dayag (Pres. & CEO)
Revenue Increase US$ 1.1 million (2010)
Steady US$ -7.9 million (2010)
Decrease US$ -7.2 million (2010)
Website www.cgen.com
Footnotes / references
[1]

Compugen (Hebrew: קומפיוג'ן‎) is a publicly traded drug discovery company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.

Operations

Compugen operates in two areas of the biotechnology industry: it develops and markets bioinformatics software platforms and engages in in silico drug discovery.[2] Over the years it has partnered with companies the likes of Pfizer, Novartis, Abbott, BioLineRx, and Seattle Genetics.[3][4][5][6][7] Amgen and Bayer are among Compugen's competitors.[8]

Pipeline

CGEN-15029

CGEN-15029 is the lead agent in their immuno-oncology product portfolio.[9]

History

Compugen was founded in 1993 by Eli Mintz, Simchon Faigler and Amir Natan. Mintz conceived of the idea for the company in 1991 while accompanying his wife, Liat Mintz, to a genomics engagement at the Pasteur Institute in France. She commented that the quantities of data being produced by scientists involved in DNA sequencing exceeded what computers could process at reasonable speeds. Eli Mintz partnered with colleagues Faigler and Natan from the IDF's elite Talpiot program to develop a more powerful computer; and indeed, the company's first computer, dubbed the "Bioccelerator," boasted speeds up to one thousand times faster than other platforms being used at the time.[2][10][11] In 1997, the company followed this success by introducing LEADS, an EST clustering and assembly platform.[12][13] By around 2001, Compugen had effected a shift in its business model from a company whose almost exclusive focus was marketing computer programs and applications to one whose operations extended into the diagnostics and therapeutics fields.[14][15]

Compugen began trading on the Nasdaq in 2000 and on the Tel Aviv Stock Exchange in 2002.[16] Also in 2002, Compugen spun off its subsidiary Evogene, established as an agriscience division in 1999.[17][18]

Management

Mor Amitai, Hebrew University alumnus (Ph.D, Mathematics), who joined Compugen in 1994, was the company's CEO and president from 1998 to 2005. He was replaced by Alex Kotzer, Technion alumnus (Chemical Engineering), who was CEO and president through 2008.[19][20][21][22] Anat Cohen-Dayag, Weizmann Institute alumnus (Ph.D, Cellular Biology), became co-CEO of Compugen in 2009, serving alongside Martin Gerstel, Yale alumnus (Engineering). She has been the company's exclusive CEO since 2010.[23][24]

See also

References

  1. ↑ "CGEN Income Statement". Yahoo! Finance. 2011. Retrieved 13 December 2011.
  2. 1 2 Khavul, Susanna (2005). "Chapter 4: Israel". In Simon Commander. The Software Industry in Emerging Markets. Gloucestershire, United Kingdom: Edward Elgar Publishing. pp. 174–175. ISBN 1-84542-247-3. Retrieved 13 December 2011.
  3. ↑ Marcial, Gene G. (10 September 2001). "Promising Leads at Compugen". Bloomberg Businessweek. Retrieved 13 December 2011.
  4. ↑ Davies, Nick; Ahlborn, Heather; Henderson, Stuart (2006). "Chapter 32: Powerful, Predictive and Pervasive: The Future of Computers in the Pharmaceutical Industry". In Sean Ekins. Computer Applications in Pharmaceutical Research and Development. Hoboken, New Jersey: Wiley Interscience. p. 761. ISBN 978-0-471-73779-7. Retrieved 13 December 2011.
  5. ↑ "Abbott leases Compugen LEADS drug development platform". Haaretz. TheMarker. 15 January 2003. Retrieved 13 December 2011.
  6. ↑ "BioLineRx to Develop and Commercialize Novel Peptide Drug Candidates Discovered by Compugen". Yahoo! Finance (Jerusalem and Tel Aviv, Israel). Business Wire. 13 December 2011. Retrieved 13 December 2011.
  7. ↑ "Seattle Genetics, Compugen sign cancer drug deal". The Seattle Times. Associated Press. 29 October 2010. Retrieved 13 December 2011.
  8. ↑ "Compugen Ltd: Company profile from Hoover's". Hoover's. 2011. Retrieved 13 December 2011.
  9. ↑ cgen-15029 March 2016
  10. ↑ Blackburn, Nicky (12 November 2001). "Computing the benefits of genes and proteins". Israel21c. Retrieved 13 December 2011.
  11. ↑ Ginzburg, Ami (3 August 2001). תהליך האבולוציה של קומפיוג'ן [Compugen's evolution]. Haaretz (in Hebrew). Retrieved 13 December 2011. מערכת המחשב שפותחה היתה מסוגלת לבצע השוואות של רצפים גנטיים במהירות של עד פי 1,000 ממערכות אחרות.
  12. ↑ Russell, John (17 October 2005). "Compugen Transforms Its Business". Bio-ITWorld.com. Retrieved 13 December 2011.
  13. ↑ Xie, Hanqing; Gill-More, Raveh (2004). "Transcriptome Analysis Through Expressed Sequences". In Seckbach, Joseph; Rubin, Eitan. The New Avenues in Bioinformatics. Dordrecht: Kluwer Academic Publishers. p. 153. ISBN 1-4020-2639-0. Retrieved 13 December 2011.
  14. ↑ Pincas, Gitit (1 November 2004). "Compugen's metamorphosis". Globes. Retrieved 15 December 2011.
  15. ↑ Coren, Ora (4 May 2001). קומפיוג'ן עוברת לפיתוח תרופות [Compugen transitions to development of drugs]. TheMarker (in Hebrew). Retrieved 13 December 2011. לדבריו, החברה מעוניינת לזהות את ההזדמנויות ולהיות שותפה בתחומי הדיאגנוסטיקה והתרפויטיקה, לא רק למכור תוכנות ואפליקציות.
  16. ↑ "Compugen Company Profile". BioPortfolio. Retrieved 13 December 2011.
  17. ↑ Coren, Ora (18 February 2004). "Propagating the Evogene way". Haaretz. Retrieved 13 December 2011.
  18. ↑ "Evogene, a Subsidiary of Compugen, Raising U.S. $2.0 Million in Private Financing". AllBusiness.com (Tel Aviv, Israel). Business Wire. 6 January 2003. Retrieved 13 December 2011.
  19. ↑ Tsipori, Tali (13 August 2000). "Compugen to Raise $55 Mln at $280 Mln Value Tonight". Globes. Retrieved 15 December 2011.
  20. ↑ "Compugen Ltd (CGEN) – 6-K – 7/2/2003". EDGAR Online. 2 June 2003. Retrieved 15 December 2011.
  21. ↑ "Compugen Ltd – 6-K – 20080820 - Form". EDGAR Online. 2008. Retrieved 15 December 2011.
  22. ↑ "Alex Kotzer Profile". Forbes.com. Retrieved 15 December 2011.
  23. ↑ "Anat Cohen Dayag Profile – Forbes.com". Forbes. Retrieved 13 December 2011.
  24. ↑ London Sappir, Shoshana (4 March 2002). "Martin Gerstel's back in business, this time in Israel". Israel21c. Retrieved 13 December 2011.

Further reading

External links

This article is issued from Wikipedia - version of the Monday, March 07, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.